These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24169494)

  • 21. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
    Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
    Aggarwal R; Bryce A; Ryan CJ; Harzstark A; Derleth C; Kim W; Friedlander T; Lin AM; Rodvelt-Bagchi T; Dhawan M; Zhang L; Lee M; Siebeneck E; Hough J; Small EJ
    Urol Oncol; 2017 Apr; 35(4):149.e7-149.e13. PubMed ID: 28161323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
    Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
    Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A; Sternberg CN; Skoneczna I; Kovel S
    BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients.
    Medioni J; Deplanque G; Ferrero JM; Maurina T; Rodier JM; Raymond E; Allyon J; Maruani G; Houillier P; Mackenzie S; Renaux S; Dufour-Lamartinie JF; Elaidi R; Lerest C; Oudard S
    Clin Cancer Res; 2014 Sep; 20(17):4471-7. PubMed ID: 25013124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy.
    Lee JL; Eun Kim J; Ahn JH; Lee DH; Lee J; Kim CS; Hyuk Hong J; Hong B; Song C; Ahn H
    Am J Clin Oncol; 2011 Apr; 34(2):140-4. PubMed ID: 20686407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Miano ST; De Rubertis G; Barbanti G; Bianco V; Brozzetti S; Francini E
    Med Oncol; 2015 Mar; 32(3):52. PubMed ID: 25636506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
    Shen YJ; Bian XJ; Xie HY; Zhu Y; Zhang HL; Dai B; Zhang SL; Yao XD; Ye DW
    Zhonghua Wai Ke Za Zhi; 2012 Jun; 50(6):539-42. PubMed ID: 22943949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer.
    Emmenegger U; Booth CM; Berry S; Sridhar SS; Winquist E; Bandali N; Chow A; Lee C; Xu P; Man S; Kerbel RS; Ko YJ
    Oncologist; 2015 Dec; 20(12):1351-2. PubMed ID: 26542984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Safarinejad MR
    Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
    Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
    Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
    Vincenzi B; Silletta M; Schiavon G; Frezza AM; Del Vescovo R; Zobel BB; Santini D; Dei Tos AP; Tonini G
    Expert Opin Investig Drugs; 2013 Jan; 22(1):1-7. PubMed ID: 23157681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.